Hsbc Holdings PLC Has $4.37 Million Position in TG Therapeutics, Inc. $TGTX

Hsbc Holdings PLC raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 228.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 146,087 shares of the biopharmaceutical company’s stock after purchasing an additional 101,646 shares during the period. Hsbc Holdings PLC owned approximately 0.09% of TG Therapeutics worth $4,374,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Congress Asset Management Co. acquired a new stake in TG Therapeutics during the 4th quarter worth $57,307,000. Nordea Investment Management AB acquired a new position in TG Therapeutics in the fourth quarter valued at about $2,356,000. Penn Capital Management Company LLC increased its holdings in shares of TG Therapeutics by 17.6% in the third quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock worth $18,877,000 after acquiring an additional 77,895 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of TG Therapeutics by 56.1% in the third quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock worth $8,234,000 after acquiring an additional 81,907 shares in the last quarter. Finally, WINTON GROUP Ltd increased its holdings in shares of TG Therapeutics by 1,031.3% in the third quarter. WINTON GROUP Ltd now owns 125,000 shares of the biopharmaceutical company’s stock worth $4,516,000 after acquiring an additional 113,951 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and set a $83.00 target price on shares of TG Therapeutics in a research note on Monday, June 22nd. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.60.

TG Therapeutics Trading Up 4.1%

Shares of TG Therapeutics stock opened at $55.83 on Friday. The business has a fifty day simple moving average of $42.19 and a two-hundred day simple moving average of $34.57. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $57.38. The company has a market capitalization of $8.55 billion, a price-to-earnings ratio of 19.52 and a beta of 1.68. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same period last year, the firm earned $0.03 earnings per share. Research analysts forecast that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.